CO2017000271A2 - Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo - Google Patents

Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo

Info

Publication number
CO2017000271A2
CO2017000271A2 CONC2017/0000271A CO2017000271A CO2017000271A2 CO 2017000271 A2 CO2017000271 A2 CO 2017000271A2 CO 2017000271 A CO2017000271 A CO 2017000271A CO 2017000271 A2 CO2017000271 A2 CO 2017000271A2
Authority
CO
Colombia
Prior art keywords
patients
methods
improve myocardial
myocardial performance
udenafil
Prior art date
Application number
CONC2017/0000271A
Other languages
English (en)
Inventor
James L Yeager
Original Assignee
Mezzion Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mezzion Pharma Co Ltd filed Critical Mezzion Pharma Co Ltd
Publication of CO2017000271A2 publication Critical patent/CO2017000271A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente invención se refiere generalmente al campo del uso de udenafilo o una sal farmacéuticamente aceptable del mismo en pacientes que se han sometido a la operación de Fontan.
CONC2017/0000271A 2014-08-12 2017-01-12 Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo CO2017000271A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462036506P 2014-08-12 2014-08-12
US201562186132P 2015-06-29 2015-06-29
PCT/US2015/038638 WO2016025100A2 (en) 2014-08-12 2015-06-30 Methods of improving myocardial performance in fontan patients using udenafil compositions

Publications (1)

Publication Number Publication Date
CO2017000271A2 true CO2017000271A2 (es) 2017-05-31

Family

ID=55301323

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0000271A CO2017000271A2 (es) 2014-08-12 2017-01-12 Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo

Country Status (24)

Country Link
US (6) US10137128B2 (es)
EP (2) EP4342531A2 (es)
JP (4) JP2017524705A (es)
KR (3) KR20170066334A (es)
CN (1) CN107073001A (es)
AU (3) AU2015302271B2 (es)
BR (1) BR112017002675A2 (es)
CA (5) CA3128691A1 (es)
CL (1) CL2017000329A1 (es)
CO (1) CO2017000271A2 (es)
DO (1) DOP2017000014A (es)
EA (1) EA201692518A3 (es)
EC (1) ECSP17015154A (es)
IL (2) IL285193B2 (es)
MX (1) MX2017001396A (es)
MY (1) MY200278A (es)
NZ (2) NZ765796A (es)
PE (1) PE20170469A1 (es)
PH (1) PH12017500120A1 (es)
SG (2) SG11201700060WA (es)
TN (1) TN2017000029A1 (es)
TW (5) TWI730944B (es)
UA (1) UA120514C2 (es)
WO (1) WO2016025100A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170066334A (ko) 2014-08-12 2017-06-14 주식회사 메지온 유데나필 조성물을 이용하여 폰탄 환자에서 심근 성능을 개선시키는 방법
US20170112858A1 (en) * 2015-10-27 2017-04-27 New Haven Pharmaceuticals, Inc. Extended Release Aspirin
KR102249155B1 (ko) 2019-07-26 2021-05-07 주식회사 코아팜바이오 유데나필을 함유하는 약제학적 조성물
JP2022550734A (ja) * 2019-09-24 2022-12-05 メジオン ファーマ カンパニー リミテッド ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法
US20230218622A1 (en) 2021-08-13 2023-07-13 Mezzion Pharma Co., Ltd. Methods and compositions for treating fibrotic liver conditions, using udenafil compositions
WO2023121689A1 (en) 2021-12-20 2023-06-29 Mezzion Pharma Co., Ltd. Methods and compositions for improving exercise performance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US20050272741A1 (en) * 2004-01-16 2005-12-08 Jack Rychik Novel methods of treatment for Fontan patients with protein losing enteropathy
BRPI0616633A2 (pt) 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
KR100792126B1 (ko) 2006-04-04 2008-01-04 동아제약주식회사 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제
KR101002490B1 (ko) 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
CN101711153A (zh) 2007-06-13 2010-05-19 拜耳先灵制药股份公司 用于治疗听觉损伤的pde抑制剂
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101071877B1 (ko) * 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
CA2784788A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating peripheral vascular disease
CN102970965A (zh) 2010-04-05 2013-03-13 Sk化学公司 含有pde5抑制剂的减少皮肤皱纹的合成物
JP5883687B2 (ja) 2011-03-09 2016-03-15 第一三共ヘルスケア株式会社 Ｐｄｅ５阻害剤含有医薬組成物
KR101383430B1 (ko) 2012-01-26 2014-04-08 광동제약 주식회사 새로운 조합의 구강내 속붕해 필름형성 조성물 및 ｐｄｅ５ 저해제가 함유된 구강내 속붕해 필름제제
CN108452311A (zh) 2012-11-13 2018-08-28 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
KR20170066334A (ko) 2014-08-12 2017-06-14 주식회사 메지온 유데나필 조성물을 이용하여 폰탄 환자에서 심근 성능을 개선시키는 방법

Also Published As

Publication number Publication date
US20190030037A1 (en) 2019-01-31
MX2017001396A (es) 2017-12-04
US10137128B2 (en) 2018-11-27
TW202118491A (zh) 2021-05-16
EP4342531A2 (en) 2024-03-27
US20180169103A1 (en) 2018-06-21
EA201692518A3 (ru) 2017-11-30
TWI767153B (zh) 2022-06-11
US20230095034A1 (en) 2023-03-30
KR20210038708A (ko) 2021-04-07
PE20170469A1 (es) 2017-04-21
IL285193B1 (en) 2023-07-01
MY200278A (en) 2023-12-18
TW202224685A (zh) 2022-07-01
JP2017524705A (ja) 2017-08-31
US20160045510A1 (en) 2016-02-18
CA2954183A1 (en) 2016-02-18
IL285193A (en) 2021-08-31
CA2954183C (en) 2023-10-31
NZ765796A (en) 2024-02-23
CA3128697A1 (en) 2016-02-18
TW201617080A (zh) 2016-05-16
US20190030038A1 (en) 2019-01-31
IL250547B (en) 2021-07-29
DOP2017000014A (es) 2017-06-30
IL285193B2 (en) 2023-11-01
JP2024020187A (ja) 2024-02-14
BR112017002675A2 (pt) 2017-12-12
JP2021091721A (ja) 2021-06-17
TWI730944B (zh) 2021-06-21
IL250547A0 (en) 2017-03-30
TW202400176A (zh) 2024-01-01
AU2021202212A1 (en) 2021-05-06
CN107073001A (zh) 2017-08-18
TN2017000029A1 (en) 2018-07-04
US10653698B2 (en) 2020-05-19
EP3180008A2 (en) 2017-06-21
ECSP17015154A (es) 2017-05-31
AU2015302271A1 (en) 2017-01-12
KR20170066334A (ko) 2017-06-14
WO2016025100A2 (en) 2016-02-18
TW202002982A (zh) 2020-01-16
CA3128705A1 (en) 2016-02-18
JP2019077726A (ja) 2019-05-23
UA120514C2 (uk) 2019-12-26
CA3128691A1 (en) 2016-02-18
AU2015302271B2 (en) 2019-02-28
EA201692518A2 (ru) 2017-07-31
AU2019203706A1 (en) 2019-06-20
US20220047601A1 (en) 2022-02-17
CA3128680A1 (en) 2016-02-18
SG11201700060WA (en) 2017-02-27
CL2017000329A1 (es) 2017-11-03
KR20230116098A (ko) 2023-08-03
SG10202100300RA (en) 2021-02-25
EP3180008A4 (en) 2018-01-24
EP3180008B1 (en) 2023-11-29
PH12017500120A1 (en) 2017-05-29
NZ765800A (en) 2024-03-22

Similar Documents

Publication Publication Date Title
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
EA201691582A1 (ru) Новые фармацевтические препараты
CO2017003279A2 (es) Compuestos y composiciones farmacéuticamente aceptables de los mismos, eficaces como inhibidores de mk2
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
GT201400111A (es) Triazolopiridinas sustituidas
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
MX2016014564A (es) Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido.
NI201800071A (es) Compuestos de isoindol
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
CR20160495A (es) Composiciones libres de células para la restauración de células y métodos para la preparación y utilización de las mismas
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
CL2016000542A1 (es) Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis.
CR20150352A (es) Nuevas composiciones antifúngicidas